0739 ET - The FDA's approval of Alnylam's Amvuttra in the cardiomyopathy of transthyretin-mediated amyloidosis, or ATTR-CM, puts the drug well on track to achieving mega blockbuster status, Citi says. Analysts David Lebowitz and Ike Lee say the drug's label was clean and overall in line with their expectations, which they say will enable strong uptake. The green light makes Amvuttra the only U.S. drug approved to address both cardiomyopathy and polyneuropathy manifestations of ATTR amyloidosis, a factor Citi says could resonate with practitioners. Alnylam up 4.5% premarket to $265. (colin.kellaher@wsj.com)
(END) Dow Jones Newswires
March 21, 2025 07:39 ET (11:39 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.